Danish report recommends action on rare disease drugs

Treating greater numbers of Danish patients with rare diseases requires a more open and shared dialogue about handling uncertainty around the effects of the medicines used.

So says a new report from the Danish Knowledge Centre for Life Science, which has looked more closely at the importance of evidence quality for rare disease medicines. 

The center is part of the Danish pharma trade group Lif. Its report suggests that more solutions need to be developed and a broader consensus reached on how to assess new treatments for rare diseases that are based on a sparse evidence base.